Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators.

Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.

PMID:
30982686
2.

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M.

J Cancer Res Clin Oncol. 2017 Jun;143(6):1023-1034. doi: 10.1007/s00432-017-2344-3. Epub 2017 Feb 14.

PMID:
28197787
3.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.

Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.

PMID:
27776843
4.

Indication for 'Over the scope' (OTS)-clip vs. covered self-expanding metal stent (cSEMS) is unequal in upper gastrointestinal leakage: results from a retrospective head-to-head comparison.

Farnik H, Driller M, Kratt T, Schmidt C, Fähndrich M, Filmann N, Königsrainer A, Stallmach A, Heike M, Bechstein WO, Zeuzem S, Albert JG.

PLoS One. 2015 Jan 28;10(1):e0117483. doi: 10.1371/journal.pone.0117483. eCollection 2015.

5.

The Dortmund endoscopic full-thickness resection method: combination of the over-the-scope clip system and the Inoue cap.

Fähndrich M, Heike M, Sandmann M.

Endoscopy. 2014;46 Suppl 1 UCTN:E466. doi: 10.1055/s-0034-1377548. Epub 2014 Oct 14. No abstract available.

PMID:
25314198
6.

Endoscopic full-thickness resection based on the novel Dortmund technique.

Faehndrich M, Heike M, Sandmann M.

Endoscopy. 2014;46 Suppl 1 UCTN:E424. doi: 10.1055/s-0034-1377436. Epub 2014 Oct 14. No abstract available.

PMID:
25314175
7.

[Heterotopic sebaceous glands in the esophagus: case report with review of the literature].

Suttorp AC, Heike M, Fähndrich M, Reis H, Lorenzen J.

Pathologe. 2013 Mar;34(2):162-4. doi: 10.1007/s00292-012-1714-5. Review. German.

PMID:
23111754
8.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR.

BMC Cancer. 2012 Apr 11;12:144. doi: 10.1186/1471-2407-12-144.

9.

The plus of 65+.

D'Aavolio DA, Heike ME, Burke D, Gallivan T.

Nurs Manage. 2011 Nov;42(11):32-7. doi: 10.1097/01.NUMA.0000403277.19626.01. No abstract available.

PMID:
22037370
10.

Application of the OTSC system for the closure of fistulas, anastomosal leakages and perforations within the gastrointestinal tract.

Sandmann M, Heike M, Faehndrich M.

Z Gastroenterol. 2011 Aug;49(8):981-5. doi: 10.1055/s-0029-1245972. Epub 2011 Aug 2.

PMID:
21811949
11.

Removal of over the scope clips (OTSC) with an Nd:YAG Laser.

Fähndrich M, Sandmann M, Heike M.

Z Gastroenterol. 2011 May;49(5):579-83. doi: 10.1055/s-0029-1245871. Epub 2011 May 9.

PMID:
21557167
12.

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C; AWMF; AWMF.

Z Gastroenterol. 2011 Apr;49(4):461-531. doi: 10.1055/s-0031-1273201. Epub 2011 Apr 7. German. No abstract available.

PMID:
21476183
13.

A new method for placement of covered colorectal stents in the proximal colon using double balloon enteroscopy.

Fähndrich M, Sandmann M, Heike M.

Endoscopy. 2011;43 Suppl 2 UCTN:E23. doi: 10.1055/s-0030-1255895. Epub 2011 Jan 26. No abstract available.

PMID:
21271524
14.

[Gangliocytic paraganglioma--a rare cause of an upper gastrointestinal bleeding].

Sandmann M, Fähndrich M, Lorenzen J, Heike M.

Z Gastroenterol. 2010 Nov;48(11):1297-300. doi: 10.1055/s-0029-1245521. Epub 2010 Nov 1. German.

PMID:
21043008
15.

["Endoscopy in a stone quarry"--multiple pigment stones 6 weeks after delivery].

Sandmann M, Fähndrich M, Heike M.

Z Gastroenterol. 2010 Mar;48(3):401-5. doi: 10.1055/s-0028-1109642. German.

PMID:
20221994
16.

A facilitated method for endoscopic interventions at the bile duct after Roux-en-Y reconstruction using double balloon enteroscopy.

Fähndrich M, Sandmann M, Heike M.

Z Gastroenterol. 2008 Apr;46(4):335-8. doi: 10.1055/s-2007-963783.

PMID:
18393150
17.

[Pancreaticomediastinal fistula as a rare cause of recurrent pleural effusions].

Sandmann M, Fähndrich M, Heike M.

Z Gastroenterol. 2007 Oct;45(10):1056-9. German.

PMID:
17924302
18.

[ASCO-Update 2005--Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005].

Höhler T, Heike M, Lutz MP, Graeven U, Seufferlein T; American Society of Clinical Oncology.

Z Gastroenterol. 2005 Nov;43(11):1253-9. German.

PMID:
16267711
19.

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.

Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M.

Hum Gene Ther. 2005 Aug;16(8):996-1005.

PMID:
16076257
20.

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.

Moehler M, Eimermacher A, Siebler J, Höhler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M.

Br J Cancer. 2005 Jun 20;92(12):2122-8.

21.

[ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004].

Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T, Eberl T.

Z Gastroenterol. 2004 Dec;42(12):1416-24. German. No abstract available.

PMID:
15592968
22.

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Höhler T, Galle PR, Heike M, Moehler M.

BMC Cancer. 2004 Jul 20;4:38.

23.

Cross-presentation of human melanoma peptide antigen MART-1 to CTLs from in vitro reconstituted gp96/MART-1 complexes.

Staib F, Distler M, Bethke K, Schmitt U, Galle PR, Heike M.

Cancer Immun. 2004 Apr 16;4:3.

24.
25.

[ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003].

Eberl T, Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T.

Z Gastroenterol. 2003 Oct;41(10):1039-45. German. No abstract available.

PMID:
14562203
26.

Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.

Moehler M, Haas U, Siebler J, Schimanski C, Hertkorn C, Hoehler T, Galle PR, Heike M.

Anticancer Drugs. 2003 Sep;14(8):645-50.

PMID:
14501387
27.

Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells.

Moehler M, Zeidler M, Schede J, Rommelaere J, Galle PR, Cornelis JJ, Heike M.

Cancer Gene Ther. 2003 Jun;10(6):477-80.

PMID:
12768193
28.
30.

Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.

Moehler M, Hoffmann T, Zanke C, Hohl H, Burg H, Ehscheid P, Schwindt P, Adami B, Schroeder M, Klein O, Baldus M, Galle PR, Heike M.

Anticancer Drugs. 2003 Jan;14(1):79-85.

PMID:
12544262
31.

Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60.

Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, Enk AH, Galle PR, Heike M.

J Immunol. 2002 Dec 1;169(11):6141-8.

32.

[Prospective feasibility study of chest X-ray vs. thoracic MRI in breath-hold technique at an open low-field scanner].

Heussel CP, Sandner A, Voigtländer T, Heike M, Deimling M, Kuth R, Rupprecht T, Schreiber WG, Kauczor HU.

Rofo. 2002 Jul;174(7):854-61. German.

PMID:
12101475
33.

Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer.

Heike M, Frenzel C, Meier D, Galle PR.

Int J Cancer. 2000 May 15;86(4):489-93.

34.

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.

Kallen KJ, Hofmann MA, Timm A, Gödderz W, Galle PR, Heike M.

Z Gastroenterol. 2000 Feb;38(2):153-7.

PMID:
10721170
35.

Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines.

Heike M, Weinmann A, Bethke K, Galle PR.

Biochem Pharmacol. 1999 Nov 1;58(9):1381-7.

PMID:
10513981
36.
37.

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens.

Heike M, Duchmann R, May E, Schulze-Bergkamen H, Schmitt U, Meyer zum Büschenfelde KH.

Int J Cancer. 1997 Jul 29;72(3):403-7.

38.

Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells.

Heike M, Schlaak J, Heyl S, Schulze-Bergkamen H, Schmitt U, Meyer zum Büschenfelde KH.

Scand J Immunol. 1997 Feb;45(2):221-6.

39.

Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-class-II-restricted autologous T cells.

Heike M, Schmitt U, Höhne A, Huber C, Meyer zum Büschenfelde KH.

Int J Cancer. 1996 Sep 4;67(5):743-8.

40.

Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96.

Altmeyer A, Maki RG, Feldweg AM, Heike M, Protopopov VP, Masur SK, Srivastava PK.

Int J Cancer. 1996 Aug 22;69(4):340-9.

41.

Heat shock protein-peptide complexes for use in vaccines.

Heike M, Noll B, Meyer zum Büschenfelde KH.

J Leukoc Biol. 1996 Aug;60(2):153-8. Review.

PMID:
8773575
42.
43.

Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens.

Heike M, Schlaak J, Schulze-Bergkamen H, Heyl S, Herr W, Schmitt U, Schneider PM, Meyer zum Büschenfelde KH.

J Immunol. 1996 Mar 15;156(6):2205-13.

PMID:
8690910
44.

Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha.

Löhr HF, Gödderz W, Wölfe T, Heike M, Knuth A, Meyer zum Büschenfelde KH, Dippold W.

Eur J Cancer. 1995 Dec;31A(13-14):2427-8. No abstract available.

PMID:
8652290
45.

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

Bernhard H, Jäger-Arand E, Bernhard G, Heike M, Klein O, Riemann JF, Meyer zum Büschenfelde KH, Dippold W, Knuth A.

Br J Cancer. 1995 Jan;71(1):102-5.

46.

New cell lines of gastric and pancreatic cancer: distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens.

Heike M, Röhrig O, Gabbert HE, Moll R, Meyer zum Büschenfelde KH, Dippold WG, Knuth A.

Virchows Arch. 1995;426(4):375-84.

PMID:
7599790
47.

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells.

Herr W, Wölfel T, Heike M, Meyer zum Büschenfelde KH, Knuth A.

Cancer Immunol Immunother. 1994 Aug;39(2):93-9.

PMID:
8044834
48.

Protective cellular immunity against a spontaneous mammary carcinoma from ras transgenic mice.

Heike M, Blachere NE, Srivastava PK.

Immunobiology. 1994 Jun;190(4-5):411-23.

PMID:
7982724
49.

[Adjuvant and palliative therapy for colorectal carcinoma].

Heike M, Wölfel T, Meyer zum Büschenfelde KH, Knuth A, Dippold WG.

Dtsch Med Wochenschr. 1994 May 27;119(21):778-85. Review. German. No abstract available.

PMID:
7514969
50.

Membranes activate tumor- and virus-specific precursor cytotoxic T lymphocytes in vivo and stimulate tumor-specific T lymphocytes in vitro: implications for vaccination.

Heike M, Blachere NE, Wölfel T, Meyer zum Büschenfelde KH, Störkel S, Srivastava PK.

J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):165-74.

PMID:
8032539

Supplemental Content

Support Center